摘要
目的研究蒽环类联合紫杉类化疗药新辅助化疗方案治疗乳腺癌的临床疗效和安全性。方法选取2012年1月至2013年6月我院收治的76例乳腺癌患者,依据治疗方案分为观察组和对照组,每组均38例。收集患者年龄、家族史、肿瘤转移等一般临床资料,对比分析两组患者治疗后临床疗效和药物不良反应情况,对比两组患者治疗后总体生存数据。结果观察组的总体治疗有效率(92.1%)显著高于对照组(71.0%),差异有统计学意义(P<0.05)。两组患者用药不良反应发生率比较差异无统计学意义(P>0.05)。随访生存分析结果显示,治疗后观察组患者的总体生存时间为(59.1±4.3)个月,显著长于对照组的(51.3±4.5)个月,差异有统计学意义(P<0.05)。结论蒽环类联合紫杉类化疗药物的新辅助化疗方案治疗乳腺癌疗效较好,安全性高,可提高患者预后生存时间。
Objective To reveal the efficacy and safety of anthracyclines in combination with taxanes for neo-adjuvant chemotherapy in patients with breast cancer.Methods From January 2012 to June 2013,76 patients with breast cancer in our hospital were divided into observation group and control group,38 cases in each group.Age,family history,tumor metastasis and other general clinical data were collected.The clinical efficacy and adverse drug reactions of the two groups were compared and analyzed.The overall survival data of the two groups were compared.Results The total effective rate of treatment in observation group(92.1%)was significantly higher than that in control group(72.0%).There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).The follow-up survival analysis showed that the overall survival time of the observation group[(59.1±4.3)months] was significantly longer than that of the control group[(51.3±4.5)months] after treatment,and the difference was statistically significant(P<0.05).Conclusion The new adjuvant chemotherapy regimen of anthracycline combined with taxanes is effective and safe in the treatment of patients with breast cancer,and it can improve the prognosis and survival time of patients.
作者
张尧天
温凤云
于子涵
张娜
ZHANG Yao-tian;WEN Feng-yun;YU Zi-han;ZHANG Na(Department of Breast Radiotherapy,Liaoning Cancer Hospital & Institute,Shenyang 110042,China;Department of Chest Radiotherapy,Liaoning Cancer Hospital & Institute,Shenyang 110042,China;Department of Gastroenterology,Jinqiu Hospital,Shenyang 110016,China)
出处
《实用药物与临床》
CAS
2019年第3期261-263,共3页
Practical Pharmacy and Clinical Remedies
